Adtralza

During treatment with tralokinumab, there is a risk of conjunctivitis, which should be treated with standard therapy.‍‍‍‍‍‍​​​‍​​​​​​ If the inflammation does not resolve following medication, the patient should be referred for an ophthalmological examination. Before initiating therapy, it is recommended that patients are brought up to date with their vaccination schedule. Particular attention should be paid to vaccinations using live and attenuated microorganisms. There are no studies confirming the safety and efficacy of such vaccines during concomitant use of tralokinumab. Patients with confirmed parasitic infections were excluded from clinical trials. Due to the immunosuppressive action of tralokinumab, it is recommended that individuals with confirmed parasitic infections receive treatment before initiating tralokinumab therapy. During treatment with tralokinumab, hypersensitivity reactions posing a risk to the patient may occur. If symptoms of hypersensitivity appear, administration of the drug should be immediately discontinued and appropriate supportive therapy initiated.